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The debate about what constitutes the correct treatment for COPD has recently 
intensified.1 This discussion has grumbled on ever since the first multicenter trials 
using inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) 
such as the European Respiratory Society study on chronic obstructive pulmonary 
disease (EUROSCOP) and Inhaled Steroids in Obstructive Lung Disease (ISOLDE) 
were published in the late 1990’s and the results of trials such as TORCH (TOwards 
a Revolution in COPD Health) using combination products has only added to the 
confusion.
Complex debate predominantly pertaining to statistical methodology has mud-
died the waters. Concepts such as immortal time bias and selection bias introducing 
regression to the mean are often too difficult to grasp for the average reader.
However, some of the methodological flaws identified by Suissa and colleagues2 are 
much easier to understand and solutions to these are potentially at hand. Firstly, it is 
clear trials investigating the effects of ICS on COPD may in fact be trials predominantly 
examining the effects of ICS withdrawal. It is not sufficient to state a treatment works 
simply because patients deteriorate when that treatment is withdrawn. Re-analysis of 
all data such that treatment effects are stratified according to pre-use of ICS is easy 
to do as all the data is there, as Suissa eloquently showed in his re-working of the 
OPTIMAL trial data.3 Even though most of the ICS/COPD trials have approximately 
50% of subjects on ICS at randomization, some have a much lower rate, such as in 
Szfranski and colleagues4 (26%) and this may not necessarily skew the overall conclu-
sions of the trial(s). Secondly, when assessing the impact of combination treatments 
it is imperative to present the correct 2 × 2 factorial analysis such that the impact of 
each individual component can be assessed as Suissa performed for TORCH.2 Thus it 
becomes clear the effect on mortality may be entirely long-acting β-agonists (LABA) 
dependant. The issue of systemic side effects and pneumonia in COPD patients treated 
with high doses of ICS over long periods also needs further careful evaluation.
It would be disingenuous of us to suggest ICS have no place in the management 
of COPD. We know a proportion of patients benefit from their bronchoprotective 
effect and that this subset of patients with COPD has a higher mortality risk.5 ICS are 
also indicated in the patients with more reversible COPD who probably suffer from 
concomitant asthma. It is time that some fundamental issues are addressed. We strongly 
urge the pharmaceutical industry to re-analyze the underlying data and demystify at 
least some of the methodological smog.International Journal of COPD 2009:4
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